More recently, the value of IDH1 inhibitors has now been established in pre‐clinical models as a possible anti‐cancer drug specifically active in IDH1 mutated cancer cells leading to delayed growth and the induction of differentiation (Rohle et al., 2013). Here, IDH1 is linked to cancer.